You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 10,117,909

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,117,909

Title:	Combination of an insulin and a GLP-1 agonist
Abstract:	The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Inventor(s):	Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE)
Assignee:	SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:	15/340,969
Patent Claims:	1. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 .mu.g/mL; and wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 .mu.g and about 2 mg. 2. The prefilled syringe of claim 1, wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 60 units and a dosage of AVE0010 between about 5 .mu.g and about 20 .mu.g. 3. The prefilled syringe of claim 1, wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 .mu.g and about 20 .mu.g. 4. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 20 m/ml to about 150 .mu.g/ml. 5. The prefilled syringe of claim 4, wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 25, 33, 40, 66, or 75m/mL. 6. The prefilled syringe of claim 4, wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 .mu.g/mL. 7. A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of: (a) insulin glargine or a pharmaceutically acceptable salt thereof, and (b) desPro.sup.36exendin-4(1-39)-Lys.sub.6-NH.sub.2 (AVE0010) or a pharmaceutically acceptable salt thereof; wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL, and wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 1.5 units to about 4 units of insulin glargine to 1 .mu.g of AVE0010. 8. The prefilled syringe of claim 7, wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 3 units of insulin glargine to 1 .mu.g of AVE0010.

Details for Patent 10,117,909

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/20/2000	⤷ Try a Trial	2028-10-17
Sanofi-aventis U.s. Llc	LANTUS	insulin glargine	Injection	021081	04/25/2007	⤷ Try a Trial	2028-10-17
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	12/16/2015	⤷ Try a Trial	2028-10-17
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	11/15/2019	⤷ Try a Trial	2028-10-17
Mylan Pharmaceuticals Inc.	SEMGLEE	insulin glargine	Injection	210605	06/11/2020	⤷ Try a Trial	2028-10-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.